Study (year) | Outcomes | HR(95%CI) | Adjusted confounding factors |
---|---|---|---|
Gijsberts CM (2016) [18] | Long-term mortality | 1.35 (1.14–1.59) | Leukocyte characteristics (lymphocyte cell size coefficient of variation, monocyte count) |
Kiris T (2017) [21] | 30-day mortality 36-month mortality | 8.093 (1.006–65.074) 2.374 (1.160–4.857) | Age, gender, history of stroke/TIA, history of DM, multivessel disease, Killip, albumin, LVEF, hemoglobin, RDW, MPV, serum creatinine, total bilirubin, β-blocker usage, ACEI/ARB usage |
Fan Z (2018) [22] | Long-term MACE | 2.128 (1.458–3.105) | NLR, hs-CRP, brain natriuretic peptide |
Cheng H (2019) [23] | In-hospital MACE Long-term MACE | 2.891 (1.265–8.354) 1.793 (1.169–2.515) | Age, male, body mass index, hypertension, DM, dyslipidemia, history of coronary artery disease, history of myocardial infarction, smoking index, Leukocyte, NLR, hs-CRP, gensini score |
Cai M (2019) [24] | Long-term MACE | 1.74 (1.12–2.70) | Age, sex, Killip, DM, hypertension, hyperlipidemia, PCI, β-blocker usage, ACEI/ARB usage, glucose, white blood cell, hemoglobin, ln CK-peak, MPV, RDW, LVEF, location of myocardial infarction |